https://voorwaarheid.nl/wp-content/u...orizations.pdf
europejska agencja leków napisał
You are indeed correct to point out that COVID-19 vaccines have not been authorised for
preventing transmission from one person to another. The indications are for protecting the
vaccinated individuals only.
The product information for COVID-19 vaccines clearly states that the vaccines are for active
immunisation to prevent COVID-19. In addition, EMA’s assessment reports on the authorisation of
the vaccines note the lack of data on transmissibility.
przyjmij zastrzyk, zeby chronic siebie i innych? przyjmij zastrzyk, bo zabijesz babcie? przyjmij zastrzyk, zebysmy mieli spokojne swieta i wrocili do normalnosci?
europejska agencja leków napisał
Authorisation of vaccines targeting the Omicron XBB.1.5 subvariant
You note that data from clinical trials are not available for adapted vaccines targeting Omicron
XBB.1.5 subvariant. Given this and the fact that the international public health emergency is over,
you question the need for authorising the adapted vaccines at this time.
We would like to stress that the authorisation of adapted COVID-19 vaccines is not contingent on
the continuation of the public health emergency. The authorised indications do not restrict the use
of the vaccines to an emergency.
Furthermore, data from clinical trials were not a scientific requirement for the Omicron XBB.1.5
adapted vaccines because of the information derived from the originally authorised and earlier
adapted vaccines.
In its decisions to recommend authorisation of vaccines targeting the Omicron XBB.1.5 subvariant,
EMA’s human medicines committee (CHMP) considered all the available data on both the originally
authorised vaccines and earlier adapted ones, including data on safety, efficacy and
immunogenicity (how well they trigger immune responses).
trafnia pan zauwaza, ze nie ma danych z badan klinycznych nad nowym produktem, ale to nie jest potrzebne, bo sprawdzilismy poprzednie wersje tego produktu. noz sie w kieszeni otwiera ja pierdole.
https://www.cambridge.org/core/journ...0E7A1E#article
We examined the association between face masks and risk of infection with SARS-CoV-2 using cross-sectional data from 3,209 participants in a randomized trial of using glasses to reduce the risk of infection with SARS-CoV-2. Face mask use was based on participants’ response to the end-of-follow-up survey.
We found that the incidence of self-reported COVID-19 was 33% (aRR 1.33; 95% CI 1.03 – 1.72) higher in those wearing face masks often or sometimes, and 40% (aRR 1.40; 95% CI 1.08 – 1.82) higher in those wearing face masks almost always or always, compared to participants who reported wearing face masks never or almost never.
The crude estimates show a higher incidence of testing positive for COVID-19 in the groups that used face masks more frequently, with 8.6% of participants who never or almost never used masks, 15.0% of participants who sometimes used masks, and 15.1% of participants who almost always or always used masks reporting a positive test result.
The risk was 1.74 (1.38 to 2.18) times higher in those who wore face masks often or sometimes and 1.75 (1.39 to 2.21) times higher in those who wore face masks almost always or always, compared to participants who reported never or almost never wore masks.
Zakładki